Canadian Biosimilar Approval May Indicate Policy Shift

June 13, 2018

Canada has generally been slow to approve biosimilar products, but its thumbs-up for Apobiologix’s biosimilar of bone marrow stimulant Neulasta (pegfilgrastim) beat regulators in the U.S. and other major markets to the punch.

Related Stories